Suppression of hepcidin during anemia requires erythropoietic activity

Blood

Volumn 108, Issue 12, 2006, Pages 3730-3735

  Pak, Mihwa ^a   Lopez, Miguel A ^a   Gabayan, Victroia ^a   Ganz, Tomas ^a,b   Rivera, Seth ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b 37 131 CHS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOXORUBICIN; HEPCIDIN; HEPCIDIN 1; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; ERYTHROPOIESIS; FEMALE; GENE EXPRESSION; HYPOXEMIA; IRON BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PHLEBOTOMY; PRIORITY JOURNAL;

EID: 33845245942     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-06-028787     Document Type: Article

References (39)

1. Finch C. Regulators of iron balance in humans. Blood. 1994;84:1697-1702.
2. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-2093.
3. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000;275:19906-19912.
4. Wallis JP, Wells AW, Whitehead S, Brewster N. Recovery from post-operative anaemia. Transfus Med. 2005;15:413-418.
5. Mosby's Drug Consult. Stat!Ref Online Electronic Medical Library (15). http://www.mosbydrugs.com. Accessed June 10, 2005.
6. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110:1037-1044.
7. Nicolas G, Viatte L, Bennoun M, et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis. 2002;29:327-335.
8. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006; [Epub ahead of print.]
9. Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest. 2005;35(suppl 3):13-19.
10. Beguin Y. Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta. 2003;329:9-22.
11. Kohgo Y, Niitsu Y, Kondo H, et al. Serum transferrin receptor as a new index of erythropoiesis. Blood. 1987;70:1955-1958.
12. Nemeth E, Origa R, Ganz T, Galanello R. Urinary hepcidin in thalassemic syndromes [abstract]. Blood. 2005;106. Abstract 3589.
13. Flanagan JM, Peng H, Lee PL, Beutler E. Analysis of the effect of soluble transferrin receptor 1 (sTfR1) on iron metabolism in mice [abstract]. 47th American Society of Hematology Annual Meeting and Exposition. 2005.
14. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811-7819.
15. Anderson GJ, Frazer DM, Wilkins SJ, et al. Relationship between intestinal iron-transporter expression, hepatic hepcidin levels and the control of iron absorption. Biochem Soc Trans. 2002;30:724-726.
16. Frazer DM, Wilkins SJ, Becker EM, et al. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology. 2002;123:835-844.
17. Ilyin G, Courselaud B, Troadec MB, et al. Comparative analysis of mouse hepcidin 1 and 2 genes: evidence for different patterns of expression and co-inducibility during iron overload. FEBS Lett. 2003;542:22-26.
18. Mazur A, Feillet-Coudray C, Romier B, et al. Dietary iron regulates hepatic hepcidin 1 and 2 mRNAs in mice. Metabolism. 2003;52:1229-1231.
19. Cutnell JD, Johnson KW. Physics. 4th ed. New York, NY John Wiley; 1997.
20. Rebouche CJ, Wilcox CL, Widness JA. Microanalysis of non-heme iron in animal tissues. J Biochem Biophys Methods. 2004;58:239-251.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e2002-2007.
22. Golab J, Olszewska D, Mroz P, et al. Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. Clin Cancer Res. 2002;8:1265-1270.
23. Hofland KF, Thougaard AV, Sehested M, Jensen PB. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin Cancer Res. 2005;11:3915-3924.
24. Kalyanaraman B, Joseph J, Kalivendi S, et al. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem. 2002;235:119-124.
25. Barbee RW, Perry BD, Re RN, Murgo JP. Microsphere and dilution techniques for the determination of blood flows and volumes in conscious mice. Am J Physiol. 1992;263:R728-R733.
26. Neumann CA, Krause DS, Carman CV, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature. 2003;424:561-565.
27. Inderbitzin D, Sidler D, Studer P, Gloor B. Mouse liver anatomy from a microsurgical point of view [abstract]. The Society for Surgery of the Alimentary Tract, May 14-19, 2005. Chicago, IL.
28. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461-2463.
29. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-1276.
30. Roy CN, Custodio AO, de Graaf J, et al. An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice. Nat Genet. 2004;36:481-485.
31. Shike H, Lauth X, Westerman ME, et al. Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge. Eur J Biochem. 2002;269:2232-2237.
32. Kelley-Loughnane N, Sabla GE, Ley-Ebert C, Aronow BJ, Bezerra JA. Independent and overlapping transcriptional activation during liver development and regeneration in mice. Hepatology. 2002;35:525-534.
33. Gervois P, Kleemann R, Pilon A, et al. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate. J Biol Chem. 2004;279:16154-16160.
34. Ramadori G, Christ B. Cytokines and the hepatic acute-phase response. Semin Liver Dis. 1999;19:141-155.
35. Moshage H. Cytokines and the hepatic acute phase response. J Pathol. 1997;181:257-266.
36. Tsuchihashi S, Ke B, Kaldas F, et al. Vascular endothelial growth factor antagonist modulates leukocyte trafficking and protects mouse livers against ischemia/reperfusion injury. Am J Pathol. 2006;168:695-705.
37. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353:1135-1146.
38. Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood. 2005;105:4103-4105.
39. Rachmilewitz EA, Weizer-Stern O, Adamsky K, et al. Role of iron in inducing oxidative stress in thalassemia: can it be prevented by inhibition of absorption and by antioxidants? Ann N Y Acad Sci. 2005;1054:118-123.